Markers of Cellular Proliferation, Apoptosis, Estrogen/Progesterone Receptor Expression and Fibrosis in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids

被引:14
|
作者
Szydlowska, Iwona [1 ]
Grabowska, Marta [2 ]
Nawrocka-Rutkowska, Jolanta [1 ]
Piasecka, Malgorzata [2 ]
Starczewski, Andrzej [1 ]
机构
[1] Pomeranian Med Univ, Dept Gynecol Endocrinol & Gynecol Oncol, PL-71252 Szczecin, Poland
[2] Pomeranian Med Univ, Dept Histol & Dev Biol, Zolnierska 48 St, PL-71210 Szczecin, Poland
关键词
uterine myoma; ulipristal acetate; proliferation; apoptosis; fibrosis; estrogen receptor; progesterone receptor; ULIPRISTAL ACETATE; EXTRACELLULAR-MATRIX; ESTROGEN-RECEPTORS; GNRH AGONIST; IN-VIVO; LEIOMYOMA; MYOMA; ENDOMETRIOSIS; MECHANISMS; REDUCTION;
D O I
10.3390/jcm10040562
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There appear to be very few data on the exact mechanisms of a selective progesterone receptor modulator action in myomas. The aim of the study was to assess the effects of ulipristal acetate (UPA) on fibroids, especially on estrogen receptor (ER) and progesterone receptor (PR) immunoexpression, proliferation, apoptosis and tissue fibrosis, and to compare the above parameters in untreated (surgical attention only) and UPA-treated leiomyomas. UPA-treated patients were divided into three groups: (1) good response (>= 25% reduction in volume of fibroid), (2) weak response (insignificant volume reduction) and (3) no response to treatment (no decrease or increase in fibroid volume). The study observed a significant decrease in the percentage of collagen volume fraction and ER and PR immunoexpression in the good response group, in the percentage of proliferating cell nuclear antigen (PCNA)- and Ki67-positive cells in the groups with good and weak reactions vs. control group; significantly higher apoptotic index (terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)-positive cells) in the good reaction group vs. control group. The results of the study indicate that a good response to UPA, manifested by a volume reduction of myoma, may be associated with a decrease in fibrosis, ER/PR and PCNA and Ki67 immunoexpression and an increase in cell apoptosis within the myoma.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [1] Markers of Inflammation and Vascular Parameters in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids
    Szydlowska, Iwona
    Grabowska, Marta
    Nawrocka-Rutkowska, Jolanta
    Kram, Andrzej
    Piasecka, Malgorzata
    Starczewski, Andrzej
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)
  • [2] Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate
    Donnez, Jacques
    Donnez, Olivier
    Dolmans, Marie-Madeleine
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (12) : 1679 - 1686
  • [3] Pretreatment of Uterine Fibroids Using a Selective Progesterone Receptor Modulator - Ulipristal Acetate
    Thompson, M.
    Wong, M.
    Opemuyi, I.
    Madipola, N.
    Ramadan, T.
    Nnochiri, A.
    Guttman, J.
    20TH WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY (COGI), 2015, : 205 - 210
  • [4] Endometrial Morphology After Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator, Ulipristal Acetate
    Williams, Alistair R. W.
    Bergeron, Christine
    Barlow, David H.
    Ferenczy, Alex
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2012, 31 (06) : 556 - 569
  • [5] Selective Progesterone Receptor Modulator(ulipristal acetate - a new option in the pharmacological treatment of uterine fibroids in women
    Szamatowicz, Marian
    Kotarski, Jan
    GINEKOLOGIA POLSKA, 2013, 84 (03) : 219 - 222
  • [6] Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids
    Szydlowska, Iwona
    Marciniak, Aleksandra
    Nawrocka-Rutkowska, Jolanta
    Ryl, Aleksandra
    Starczewski, Andrzej
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (03)
  • [7] Effect of ulipristal acetate, a selective progesterone receptor modulator (SPRM), on fibroid size in women with symptomatic uterine fibroids
    Armstrong, A.
    Nieman, L. K.
    HUMAN REPRODUCTION, 2010, 25 : I90 - I91
  • [8] Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate
    Rabe, Thomas
    Saenger, Nicole
    Ebert, Andreas D.
    Roemer, Thomas
    Tinneberg, Hans-Rudolf
    De Wilde, Rudy Leon
    Wallwiener, Markus
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [9] The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids
    Bouchard, Philippe
    Chabbert-Buffet, Nathalie
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2017, 40 : 105 - 110
  • [10] Effect of a Selective Progesterone Receptor Modulator on Induction of Apoptosis in Uterine Fibroids In Vivo
    Horak, Petr
    Mara, Michal
    Dundr, Pavel
    Kubinova, Kristyna
    Kuzel, David
    Hudecek, Robert
    Chmel, Roman
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2012, 2012